biostudies-literatureHosseini TMUniversity of California San Diego Altman Clinical and Translational Research InstituteNCI NIH HHS1072https://www.ebi.ac.uk/biostudies/studies/S-EPMC11987906biostudies-literatureUnknown17(7)<b>Background/Objectives</b>: HPV+ head and neck squamous cell carcinoma has been shown to have a unique genomic background, requiring researchers to study it as its own distinct type of cancer. HPV+ tumors have been shown to exhibit fewer genetic mutations in cancer drivers as opposed to their HPV- counterparts. In this paper, we explored how targeting post-transcriptional changes, specifically alternative splicing events, could serve as a potential mechanism to treat HPV+ cancer. <b>Methods</b>: Using indisulam, a drug that targets alternative splicing through the degradation of RBM39, we treated various HPV+ and HPV- cell lines and assessed tumor cell viability. We also tested indisulam in vivo to evaluate its effect on tumor volume. Additionally, we analyzed gene expression differencesCancersIndisulam Shows an Anti-Cancer Effect on HPV+ and HPV- Head and Neck Cancer.PMC119879061KL2TR0014441K08CA276999-01A1Jang SSGuo THosseini TMBendik JfalseIndisulam Shows an Anti-Cancer Effect on HPV+ and HPV- Head and Neck Cancer.<b>Background/Objectives</b>: HPV+ head and neck squamous cell carcinoma has been shown to have a unique genomic background, requiring researchers to study it as its own distinct type of cancer. HPV+ tumors have been shown to exhibit fewer genetic mutations in cancer drivers as opposed to their HPV- counterparts. In this paper, we explored how targeting post-transcriptional changes, specifically alternative splicing events, could serve as a potential mechanism to treat HPV+ cancer. <b>Methods</b>: Using indisulam, a drug that targets alternative splicing through the degradation of RBM39, we treated various HPV+ and HPV- cell lines and assessed tumor cell viability. We also tested indisulam in vivo to evaluate its effect on tumor volume. Additionally, we analyzed gene expression differences2025-01-01T00:00:00Z2025 Mar2025-07-03T03:06:05.869Z2025-07-03T03:06:05.869ZS-EPMC119879064022760210.3390/cancers17071072